Sympathetic Vascular Transduction Across the Menopause Transition: Contributing Mechanisms

University of Missouri (MU)

Status and phase: Not yet enrolling; Early Phase 1

Conditions: Menopause

Treatments: Drug: Propranolol Hydrochloride; Drug: Phentolamine Injection

Study type: Interventional

Funder types: Other

Identifiers

NCT06787066

2125473

Details and patient eligibility

About

The investigators aim to assess the interactions between the sympathetic nervous system and the vasculature in women across the menopause transition to better understand why aging women have a higher risk of cardiovascular disease.

Enrollment: 75 estimated patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Assigned female at birth
• 18-70 years of age
• Body mass index (BMI) <30 kg/m2

Exclusion criteria

• Assigned male at birth
• Pregnancy, breastfeeding
• Body mass index ≥30 kg/m2
• Oral hormonal contraception in last 6 months, history of hormone replacement therapy, oophorectomy
• Current smoking/nicotine use
• Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy
• Nerve/neurologic disease
• Cardiovascular, hepatic, renal, respiratory disease
• Blood pressure ≥140/90 mmHg
• Diabetes, Polycystic ovarian syndrome
• Communication barriers
• Prescription medications

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

75 participants in 1 patient group

Women

Other group

Description:

Women ages 18-70 years will participate.

Treatment:

Drug: Phentolamine Injection

Drug: Propranolol Hydrochloride